cyrilzakka/clinical-trials huggingface dataset:
Food Survey, Curbside, Remote APPS - Laboratory

Participants will perform the FoodImage app in the lab. A survey will be provided after the study visit. Also the bag of combined waste will be given to a hired contractor who will sort and weigh the waste, thus creating a second estimate of waste and its key components using standard industry practices (i.e. curbside).

he Lab Study will be conducted at PBRC and will include participants (N=25) from a wide array of social and economic groups will be recruited and trained on the use of the FoodImage app. Participants use the app to measure food waste (including foods with inedible parts) created during a simulated meal preparation setting, a simulated meal consumption setting with plate waste, and a simulated cabinet and refrigerator clean-out of spoiled and out-of-date foods, where the number of items and the amounts of waste for each task is randomly assigned across participants and blinded from the research staff evaluating images and coding data. These participants will denote the normal discard destination (I.e., garbage, sink/disposal, feed to animal, compost) for each item as if the waste had occurred in their own home. The resulting photos will be processed, and data created using the methods detailed in our previously published work.

All foods to be measured by the participant during each task will be weighed by staff. Then, the items that participants note as suitable for discard via sink, garbage disposal, fed to pet or compost in their own homes are set aside and appropriately documented with the remaining items thrown in a standard trash bag that also contains waste amounts and types that mirror US solid municipal waste figures (about 80% of waste is non-food). The bag of combined waste will be given to a hired contractor who will sort and weigh the waste, thus creating a second estimate of waste and its key components using standard industry practices.

Three to five days after completing the lab tasks, participants will receive the retrospective online survey and complete it for the tasks they completed during the lab study. Estimates of food waste (edible portions only) will be constructed from the survey results using methods previously described.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, age 18-62 years
* Has an iPhone 9s or later, operable Apple ID, password, and email address that they are willing and able to use to collect data during the study. Subject acknowledges data usage and associated charges are a result of study participation. Willing to complete all study procedures and adhere to study timelines.

Exclusion Criteria:

* Refusal or unable to use an iPhone for study related purposes
* Not willing to adhere to study procedures and study visit timelines.
* Any condition or circumstance that in the judgement of the PI could interfere with study participation.
Intracytoplasmic Sperm Injection Preparation in Infertile Women

Infertility is a common gynecological problem is women

Intracytoplasmic sperm injection is one of the aisted reproduction techniques that help to solve this problem

Eligibility Criteria:
Inclusion Criteria:

* Women who have infertility with age between 20 -42 years

Exclusion Criteria:

* women who has ovarian or endometrial factor of infertility
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

This study will be an open label, dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated daily quaque die (QD) doses given over 21 days (Day 3 to Day 23) to sequential cohorts of subjects with Parkinson's disease. Each cohort will have 2 study periods. For each cohort, subjects will enter Period 1 and if they meet criteria, approximately 12 subjects will be enrolled into Period 2 and dosed with PF 06649751. Based on results observed in a previous study, Cohorts 1 and 2 will not be conducted. Cohorts 3 - 6 will test doses uptitrated to 5 mg, 15 mg and 25 mg QD. Doses may be modified based on emerging safety, tolerability and PK data, but the maximum daily dose that will be given in any cohort will have PK predictions at steady state that are anticipated to be below toxicokinetic limits. An option for down titration to the previous dose level is available should the investigator consider that an AE is intolerable. Following down titration, a single up titration to the next dose level may be attempted if the subject remains symptom free for at least 48 hrs. Safety, tolerability and PK data of Cohort 3 will be reviewed prior to initiating the dosing in Cohorts 4 and 5. Available safety, tolerability and PK data up to Day 24 of at least 5 subjects from Cohorts 4 will be reviewed prior to initiating the dosing in Cohort 6.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of idiopathic Parkinson's Disease with at least 2 out of 3 cardinal characteristics (tremor, rigidity, bradykinesia)
* Mini-Mental State Examination (MMSE) ≥ 25
* Hoehn \& Yahr Stage I-III inclusive
* Documented history of end of L-Dopa wearing OFF
* Cohort 5 only: History of dyskinesia following L-Dopa dosing and Score of at least 2 on Part IV, item 4.2 (functional impact of dyskinesia) of the MDS-UPDRS

Exclusion Criteria:

* Atypical/secondary parkinsonism
* History of surgical intervention for Parkinson's Disease
* Dementia/cognitive impairment that can interfere with study assessments
Glycoproteomic Analysis of Urine in Women Undergoing Spontaneous Preterm Delivery

When babies are premature, or born before they are fully developed, they face many different medical problems, some of which are quite devastating, such as cerebral palsy, mental retardation, blindness, deafness, severe intestinal problems, and developmental delays. Unfortunately, in more than half the cases of premature births, there is no procedure or test that an obstetrician can employ to predict if a fetus is at risk for premature birth, especially when the mother is healthy. This study seeks to determine if certain factors found in the urine undergo specific changes that can be used to detect premature births of this type before they happen.

In this study, the investigators will identify women with a history of preterm delivery between 24-32 weeks, 32-34, and 34-36 weeks gestation based on diagnosis codes in the medical record who are currently pregnant. The investigators will ask these women when they are in the 16-20 week into their pregnancy to fill out a questionaire to determine study eligibility. If chosen to participate, the investigators will ask them to collect their first morning urine samples before each of their remaining prenatal care appointments for our studies. The investigators will also ask them if the investigators can check their medical records to determine if they later had a premature baby. If these women in either group give birth prematurely, then the investigators will analyze the glycoproteins in their urine samples using known values from women who did not have a premature birth as controls. If the investigators can see any changes in glycosylation in the women who gave birth prematurely, then this information will be used to apply for a larger study that will determine if such changes apply to all women. If it can then be shown to apply to all women, then the investigators may use it to predict preterm delivery. This information would allow physicians to design treatments to help these women and their babies, and spare them these disabilities. Some women go into labor prematurely, well before they should give birth. Physicians can intervene in some cases to stop labor, and allow the fetus to develop further in the mother's womb. However, in more than half the cases the physician cannot stop this process, and the baby is born prematurely.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant women with a history of preterm delivery

Exclusion Criteria:

* Individuals that abuse alcohol or drugs
* Individuals under the age of 18
* Individuals that do not speak fluent English
* Individuals with multifetal gestation
* Individuals with known fetal anomaly
* Individuals receiving heparin treatment during current pregnancy
* Individuals with current or planned cervical cerclage
* Individuals with hypertension requiring medication
* Individuals with a seizure disorder
* Individuals who plan to deliver at some location other than the University of Missouri affiliated hospitals
* Individuals with a known abnormal fetal karyotype
Prospective Natural History Study of Retinitis Pigmentosa

This is natural history study of rods and cones degenerations in patients with Retinitis Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6a or PDE6b gene mutations.

This is an open, longitudinal, prospective, multicentric study to describe the disease progression in patients with retinitis pigmentosa due to mutation in genes with selective expression in rods: rhodopsin (RHO), phosphodiesterase 6a (PDE6a) or phosphodiesterase 6b (PDE6b).RHO,PDE6A or PDE6B mutation.

Eligibility Criteria:
Inclusion Criteria:

* RP with mutations affecting the RHO, PDE6A and PDE6B genes
* Visual acuity ≥ 20/200 for at least one eye at inclusion visit
* Binocular Visual field diameter ≥ 5° as measured on the Goldmann III-4e isopter at inclusion visit
* Patients having signed the informed consent form
* Sufficient knowledge of the local language to ensure understanding of the tasks to be performed and the instructions received
* Patient affiliated to a Health Security System if they are included in a clinical site based in France (per law)

Exclusion Criteria:

* Patients with any other gene mutation known to be involved in RP
* Patients with other ocular disorder likely to impact the retinal function
* Pregnant or breastfeeding women
Water Soluble Vitamins and Trace Elements Loss in Hemodiafiltration Patients

End stage renal disease is a severe pathology in which some toxic waste and an excessive amount of water can accumulate in the human body with life threatening consequences. Maintenance hemodialysis is one of the possible treatment for this disease.

Hemodialysis filter the blood through a membrane according to a dialysis bath and so can be able to purify the blood of the toxic waste.

Otherwise, since the 1980s, the investigator know that patient in maintenance hemodialysis can have some deficiency in water soluble vitamins and trace elements. Mechanisms of the deficiency are multiple (a decreased of food intake, a diminution of the appetite, digestive malabsorption du to medics and comorbidities and loss in hemodialysis).

Impact of this deficiency have an important impact on vital prognosis for these patients. These nutrients are essential for AND synthesis, mechanism of inflammation, cells membranes synthesis, etc. DOPPs study in 2004 have shown a decreased of 16% in the mortality within 4 years with supplemented patients. Also, since this study, international recommendations were wrote in 2009, then in 2020, in order to supplement in vitamins and trace elements patients in maintenance conventional hemodialysis.

Despite these recommendations, some supplementary efforts are necessary, especially since online hemodiafiltration, a new process, is widely available and used in particular in Europe. This process combines 2 phenomena, diffusion and convection, through high-flux membranes. This process can remove a large quantity of molecule present in blood and especially the middle-molecule. In return, a more important quantity of water soluble vitamins and oligo-elements could be removed by this technique.

Also, the investigator would like to measure this loss of vitamins and trace-elements in patients with maintenance online post-dilution hemodiafiltration process with dialysate sample and blood concentrations measured (usual patient monitoring) during the session.


Eligibility Criteria:
Inclusion Criteria:

* Maintenance hemodialysis more than 3 months
* 3 sessions per week during 4 hours
* Hemodiafiltration process used with this patient on Lyon Sud Hospital
* Flow of the vascular access \> 300 mL/min at least
* Age \> 18 years
* Patient able to understand the study's goal

Exclusion Criteria:

* Active infectious or inflammatory disease
* Active malignant disease
* Intestinal malabsorptive disease
* Polysulfone's dialysis membrane allergy
* Patient under guardianship and judicial protection
* Pregnant and breastfeeding woman
* Opposition to the study
PiXL for Correction of Hyperopia

This clinical study aims to investigate the efficacy and safety of PiXL in the refractive correction of low hyperopia.

This clinical study aims to investigate the efficacy and safety of PiXL in the refractive correction of low hyperopia.Slightly modified settings from previously published study is applied to eyes with low hyperopia with an expected refractive change of 0.75 D. Aim is to evaluate the refractive outcome of this procedure.

Eligibility Criteria:
Inclusion Criteria:

* low hyperopia of spherical equivalent from +0.5 up to +1.75 D sp. eq.
* astigmatism up to 0.75 Dcyl
* corneal thickness above 400 µm
* endothelial cell density above 1500 cell/mm2

Exclusion Criteria:

* any prior corneal surgery or any eye surgery within the last 3 months,
* any corneal pathology e.g. corneal scar or dystrophy
* unstable refraction
* patient not able to understand and sign informed consent
* patients with connective tissue disorder or uncontrolled diabetes
* pregnant or lactating women
* aphakic eyes or pseudophakic eyes without UV blocking IOL
NPWTi on Closure of Chronic Pressure Sores

The primary objective of this study is to assess the effectiveness of the Negative Pressure Wound Therapy system with instillation therapy (NPWTi) on closure of chronic pressure sores. This intervention will be compared to wet-to-dry dressings, which is standard of care. In this post-market, on-label study, we hope to show that the NPWTi system more effectively closes pressure sores following debridement than traditional care.


Eligibility Criteria:
Inclusion Criteria:

1. Ischial and sacral wounds at stage 3 and 4.
2. Any pressure sore that has the potential for a good seal.

Exclusion Criteria:

1. Any pressure sore that does not have potential for a good seal.
2. Patients with fecal incontinence (due to potential for pressure sore to be near the anus).
3. Patients who by the opinion of the Principal Investigator are not candidates for surgical closure (age, BMI, comorbidities, etc.).
4. Patients who are pregnant. This is standard of care for surgery anyway, and there is uncertainty of how both the surgery and intervention would affect the fetus. We therefore stress any form of birth control, abstinence, and method to prevent pregnancy for those enrolled in the study.
The Effect Of Simvastatin On Bone Remodeling In Socket Of Mandibular Teeth

Simvastatin has been reported to promote osteoblastic activity and inhibit osteoclastic activity by enhancing the expression of BMP2. There have been many studies demonstrating the bone-promoting effect of local application various animal models including after application into socket of teeth in a rat. the purpose of the study is to investigate the effect of slow release topical simvastatin in socket of mandibular teeth on bone remodeling in the socket

after extraction of mandibular single root teeth 10 mg of slow release simvastatin would be inserted to the socket. observation will be at 1 week, 4 weeks and 3 months.after 3 months the patients will have dental CT as done routinely in our clinic before placing dental implants and the bone density and height will be measured on this data. during the procedure of inserting a dental implant a trephine will be taken for histology.

Eligibility Criteria:
Inclusion Criteria:

* need extraction of single root tooth
* intend to have prosthetic implant in place of extraction

Exclusion Criteria:

* treated with simvastatin P.O for hypercholesterolemia
Preschool Based Obesity Prevention Effectiveness Trial

The purpose of this study is to compare changes in body mass index (BMI) among 3- to 5-year-old minority children randomized to a weight control intervention (WCI) or a general health control intervention.

BACKGROUND:

Obesity is epidemic in the U.S. and is associated with increased risk for numerous medical problems. Many obesity-related risk factors are strikingly apparent in minority populations. Ethnic differences in obesity related risk factors begin as early as six to nine years of age. Thus, the need for overweight prevention efforts as early as the preschool years is critical.

This study builds upon the findings of the "Hip-Hop to Health" program. The primary aim of Hip-Hop was to compare changes in body mass index (BMI \[kg/m2\]) in two groups of 3- to 5-year-old minority children randomized to a Weight Control Intervention (WCI) or a General Health Control Intervention (GHI). Results for the children at the Year 1 and 2 follow-ups showed that children in the WCI had significantly smaller relative changes in BMI compared to children in the GHI control group. The success was among the schools that served predominantly Black children. Hip-Hop to Health was an efficacy trial delivered by trained specialists in early childhood education, and the first efficacy trial to document change in BMI in preschool children.

DESIGN NARRATIVE:

This study will test a 14-week teacher-delivered weight control intervention (TD-WCI) to a 14-week teacher delivered general health control intervention (TD-GHI) in a randomized community trial occurring in 16 preschools in the Chicago School District. The study has the following aims: 1) to compare children in these two conditions on changes in BMI post intervention and at Year 1 follow-up; 2) to compare children in these two conditions on changes in television viewing, physical activity, and fat, fiber, fruit and vegetable intake at post-intervention and Year 1 follow-up; and 3) to compare classroom teachers in these two conditions on nutrition and exercise knowledge, nutrition attitudes, and support for healthy eating post-intervention and Year 1 follow-up.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Eligibility Criteria:
Inclusion Criteria:

* Have received an annual physical
* Parent or guardian willing to give informed consent
* Parent or guardian willing to provide demographic and anthropometric data and agree to complete food intake and physical activity information for their child

Exclusion Criteria:

* Requires a specialized diet outside of that served by the Chicago Public Schools
* Has a chronic physical or behavioral disorder that requires participant to be under close medical psychological supervision and routinely absent from the study
Virtual Reality on Pulmonary Function After Upper Abdominal Surgeries

After upper abdomen surgery, respiratory muscle dysfunction is well recognised. After laparotomy and even laparoscopy, maximum static inspiratory and expiratory pressures are lowered, and recovery can take several days. A variety of reasons have been implicated in such respiratory muscle dysfunction, including irritation and inflammation, as well as injuries near the diaphragm, resulting in local mechanical failure, reflex inhibition, and pain.

Virtual reality (VR) encourages an environment that attempts to create a moment of entertainment, motivation, and enjoyment with a variety of stimuli, with movements that stimulate physical and cognitive development, as well as the patient's active participation in the rehabilitation process. It is possible to assist in the alleviation of pain using the platform, at a low cost, through the playfulness given during rehabilitation, with an effective consumption of oxygen, range of motion, and use of the respiratory muscles more efficiently.

Participants with upper abdominal surgery will be randomly distributed into Group A (VR Group) which will receive VR for plus conventional physical therapy program and Group B (Control Group) which will receive conventional physical therapy program.

Eligibility Criteria:
Inclusion Criteria:

1. Patients undergone open upper abdominal surgery (hernia repair, cholecystectomy, large bowel removal, conventional laparotomy)
2. no prior surgical intervention for esophageal, gastric, or biliary tract resection
3. age 18-60 years
4. acceptable physical condition (permitting pulmonary function and functional capacity test).

Exclusion Criteria:

1. Cerebrovascular disease
2. use of immunosuppressants within 30 days of surgery
3. cardiovascular instability
4. chest physical therapy within the 8 weeks preceding study enrollment
5. visual impairment or hearing impairment;
6. bed-ridden patients;
7. any lung disorders
8. insulin-dependent diabetes mellitus
9. less than 6-months post thoracic or cardiac surgery
10. musculoskeletal impairment
11. cognitive disorders
12. Patients undergoing laparoscopic surgery as this induces smaller changes in the postoperative breathing mechanics than laparotomy does
13. heavy smokers or alcoholism
Personalized DC Vaccine for Lung Cancer

The study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.

Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial. Patients' rebiopsy tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.

Eligibility Criteria:
Inclusion Criteria:

* pathologically confirmed non-small cell lung cancer
* failed in previous standard chemotherapy and targeted therapy
* anticipated life time \> 3month
* Karnofsky performance status 0-1
* rehabilitate from previous therapy
* adequate organ functions

Exclusion Criteria:

* mixed histological types
* tumor emergency
* abnormal coagulation condition
* contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection
* concomitant tumors
* immunological co-morbidities